Voriconazole-associated periostitis: Pathophysiology, risk factors, clinical manifestations, diagnosis, and management

Table 2 List of reporting cases with voriconazole median daily dose, median duration of therapy, and its median trough concentration in different major patient groups

Type of patients	Median voriconazole daily dose, (interquartile range), and number of cases	Median duration of voriconazole therapy in months, (interquartile range), number of cases months	Median voriconazole trough concentration in mg/L, number of cases
All patients	600 mg, (400-800 mg), 59 patients[5,7,8,10,11,13,19,21-23,26,28,30,31,33-35,42-45,47-49,51-53]	6 mo, (4.6 – 10 mo), 77 patients[5-8,10-16,18-23,26-28,30-32,35,38-45,47-53]	2.4 mg/L, 38 patients[10,11,20,22,23,26,32,34,42,44,47,51]
Solid organ transplants	400 mg, (400-450 mg), 24 patients[5,7,8,11,13,21,26,30,33-35,39,43,44,47,48]	7 mo (3 – 17 mo), 30 patients[5,7,8,11-13,16,18,21,26,30,32,35,39,43-44,47,48,50]	3.22 mg/L, 9 patients[11,26,32,34,44,47]
Hematologic malignancy and hematopoietic stem cell transplants	400 mg, (400-750 mg), 8 patients[10,11,28,31,35,49,53]	6 mo (4.3–10.5 mo), 16 patients[6,10,11,14,15,28,31,35,37,40,41,49,53]	0.885 mg/L, 2 patients[10,11]
Immunocompetent hosts	700 mg, (700-875 mg), 18 patients[23,51,52]	5.6 mo, (4.9–6.8 mo), 18 patients[23,38,51,52]	2.5 mg/L, 17 patients[23,51]